Relation of immune cell types with WHO classification. LUAD (n=82) (lepidic; n=2, acinar; n=7, papillary; n=39, micropapillary; n=11, solid; n=15, IMA; n=8) and LUSQ (n=50) (non-keratinizing; n=6, keratinizing; n=42, basaloid; n=2). (a–d) �45 of immune cell type (a), �4 of CD4+ T cell subset (b), �8 of CD8+ T cell subset (c), and %myeloid of myeloid cell type (d) are presented following the WHO classification of LUAD and LUSQ. ns; not significant. * p<0.05. **P<0.01. ***P<0.001.
Funding
Japan Agency for Medical Research and Development (AMED)
National Cancer Center Japan (NCC)
MEXT | Japan Society for the Promotion of Science (JSPS)
History
ARTICLE ABSTRACT
The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in constructing subtype-specific immune tumor microenvironments. These classifications of NSCLC based on TIL status are useful for developing personalized immune therapies for NSCLC.